Short communication: CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41

Nathan W Cummins, Jacqueline Neuhaus, Amy M. Sainski, Michael A. Strausbauch, Peter J. Wettstein, Sharon R. Lewin, Montserrat Plana, Stacey Rizza, Zelalem Temesgen, Giota Touloumi, Matthew Freiberg, James Neaton, Andrew David Badley

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Most patients on suppressive antiretroviral therapy (ART) experience improvements in CD4 T cell count. However, some patients with undetectable viral load continue to lose CD4 T cells for unknown reasons. Casp8p41 is a host-derived protein fragment that is present only in productively infected cells and that causes the death of HIV-infected cells. We questioned whether ongoing CD4+ T cell losses while on suppressive ART were associated with subclinical HIV replication causing production of Casp8p41. We analyzed the association of Casp8p41 content with subsequent CD4 losses in patients on continuous suppressive ART and in patients who discontinued ART after Casp8p41 content was determined, adjusting for age, baseline CD4+ T cell count, and baseline HIV RNA level. Casp8p41 expression in memory CD4+ T cells was measured by intracellular flow cytometry and was correlated with viral load and CD4+ T cell change over time. In patients who stopped therapy after Casp8p41 content was determined, baseline Casp8p41 content did not predict CD4+ T cell change. However, in patients on continuous ART, higher baseline Casp8p41 content was associated with a greater odds of a CD4+ T cell decline at 6 months (p=0.01). Therefore, patients on suppressive ART, who have ongoing production of Casp8p41, have an increased risk of CD4 T cell losses, suggesting that subclinical HIV replication is driving both Casp8p41, which in turn causes a CD4+ T cell decline.

Original languageEnglish (US)
Pages (from-to)476-479
Number of pages4
JournalAIDS Research and Human Retroviruses
Volume30
Issue number5
DOIs
StatePublished - May 30 2014

Fingerprint

Communication
T-Lymphocytes
HIV
Therapeutics
CD4 Lymphocyte Count
Viral Load
Cause of Death
Flow Cytometry
Cell Death
RNA
Proteins

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Short communication : CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41. / Cummins, Nathan W; Neuhaus, Jacqueline; Sainski, Amy M.; Strausbauch, Michael A.; Wettstein, Peter J.; Lewin, Sharon R.; Plana, Montserrat; Rizza, Stacey; Temesgen, Zelalem; Touloumi, Giota; Freiberg, Matthew; Neaton, James; Badley, Andrew David.

In: AIDS Research and Human Retroviruses, Vol. 30, No. 5, 30.05.2014, p. 476-479.

Research output: Contribution to journalArticle

Cummins, Nathan W ; Neuhaus, Jacqueline ; Sainski, Amy M. ; Strausbauch, Michael A. ; Wettstein, Peter J. ; Lewin, Sharon R. ; Plana, Montserrat ; Rizza, Stacey ; Temesgen, Zelalem ; Touloumi, Giota ; Freiberg, Matthew ; Neaton, James ; Badley, Andrew David. / Short communication : CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41. In: AIDS Research and Human Retroviruses. 2014 ; Vol. 30, No. 5. pp. 476-479.
@article{cfc0e5abba8148af97355bdc7f5608e7,
title = "Short communication: CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41",
abstract = "Most patients on suppressive antiretroviral therapy (ART) experience improvements in CD4 T cell count. However, some patients with undetectable viral load continue to lose CD4 T cells for unknown reasons. Casp8p41 is a host-derived protein fragment that is present only in productively infected cells and that causes the death of HIV-infected cells. We questioned whether ongoing CD4+ T cell losses while on suppressive ART were associated with subclinical HIV replication causing production of Casp8p41. We analyzed the association of Casp8p41 content with subsequent CD4 losses in patients on continuous suppressive ART and in patients who discontinued ART after Casp8p41 content was determined, adjusting for age, baseline CD4+ T cell count, and baseline HIV RNA level. Casp8p41 expression in memory CD4+ T cells was measured by intracellular flow cytometry and was correlated with viral load and CD4+ T cell change over time. In patients who stopped therapy after Casp8p41 content was determined, baseline Casp8p41 content did not predict CD4+ T cell change. However, in patients on continuous ART, higher baseline Casp8p41 content was associated with a greater odds of a CD4+ T cell decline at 6 months (p=0.01). Therefore, patients on suppressive ART, who have ongoing production of Casp8p41, have an increased risk of CD4 T cell losses, suggesting that subclinical HIV replication is driving both Casp8p41, which in turn causes a CD4+ T cell decline.",
author = "Cummins, {Nathan W} and Jacqueline Neuhaus and Sainski, {Amy M.} and Strausbauch, {Michael A.} and Wettstein, {Peter J.} and Lewin, {Sharon R.} and Montserrat Plana and Stacey Rizza and Zelalem Temesgen and Giota Touloumi and Matthew Freiberg and James Neaton and Badley, {Andrew David}",
year = "2014",
month = "5",
day = "30",
doi = "10.1089/aid.2013.0243",
language = "English (US)",
volume = "30",
pages = "476--479",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Short communication

T2 - CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41

AU - Cummins, Nathan W

AU - Neuhaus, Jacqueline

AU - Sainski, Amy M.

AU - Strausbauch, Michael A.

AU - Wettstein, Peter J.

AU - Lewin, Sharon R.

AU - Plana, Montserrat

AU - Rizza, Stacey

AU - Temesgen, Zelalem

AU - Touloumi, Giota

AU - Freiberg, Matthew

AU - Neaton, James

AU - Badley, Andrew David

PY - 2014/5/30

Y1 - 2014/5/30

N2 - Most patients on suppressive antiretroviral therapy (ART) experience improvements in CD4 T cell count. However, some patients with undetectable viral load continue to lose CD4 T cells for unknown reasons. Casp8p41 is a host-derived protein fragment that is present only in productively infected cells and that causes the death of HIV-infected cells. We questioned whether ongoing CD4+ T cell losses while on suppressive ART were associated with subclinical HIV replication causing production of Casp8p41. We analyzed the association of Casp8p41 content with subsequent CD4 losses in patients on continuous suppressive ART and in patients who discontinued ART after Casp8p41 content was determined, adjusting for age, baseline CD4+ T cell count, and baseline HIV RNA level. Casp8p41 expression in memory CD4+ T cells was measured by intracellular flow cytometry and was correlated with viral load and CD4+ T cell change over time. In patients who stopped therapy after Casp8p41 content was determined, baseline Casp8p41 content did not predict CD4+ T cell change. However, in patients on continuous ART, higher baseline Casp8p41 content was associated with a greater odds of a CD4+ T cell decline at 6 months (p=0.01). Therefore, patients on suppressive ART, who have ongoing production of Casp8p41, have an increased risk of CD4 T cell losses, suggesting that subclinical HIV replication is driving both Casp8p41, which in turn causes a CD4+ T cell decline.

AB - Most patients on suppressive antiretroviral therapy (ART) experience improvements in CD4 T cell count. However, some patients with undetectable viral load continue to lose CD4 T cells for unknown reasons. Casp8p41 is a host-derived protein fragment that is present only in productively infected cells and that causes the death of HIV-infected cells. We questioned whether ongoing CD4+ T cell losses while on suppressive ART were associated with subclinical HIV replication causing production of Casp8p41. We analyzed the association of Casp8p41 content with subsequent CD4 losses in patients on continuous suppressive ART and in patients who discontinued ART after Casp8p41 content was determined, adjusting for age, baseline CD4+ T cell count, and baseline HIV RNA level. Casp8p41 expression in memory CD4+ T cells was measured by intracellular flow cytometry and was correlated with viral load and CD4+ T cell change over time. In patients who stopped therapy after Casp8p41 content was determined, baseline Casp8p41 content did not predict CD4+ T cell change. However, in patients on continuous ART, higher baseline Casp8p41 content was associated with a greater odds of a CD4+ T cell decline at 6 months (p=0.01). Therefore, patients on suppressive ART, who have ongoing production of Casp8p41, have an increased risk of CD4 T cell losses, suggesting that subclinical HIV replication is driving both Casp8p41, which in turn causes a CD4+ T cell decline.

UR - http://www.scopus.com/inward/record.url?scp=84899848259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899848259&partnerID=8YFLogxK

U2 - 10.1089/aid.2013.0243

DO - 10.1089/aid.2013.0243

M3 - Article

C2 - 24344953

AN - SCOPUS:84899848259

VL - 30

SP - 476

EP - 479

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 5

ER -